التفاصيل البيبلوغرافية
| العنوان: |
Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression. |
| المؤلفون: |
Koizumi, Tomonobu, Kanda, Shintaro, Kobayashi, Takashi, Iwasa, Yoh-ichiro, Matsuo, Akemi |
| المصدر: |
Chemotherapy (0009-3157); 2023, Vol. 68 Issue 3, p160-167, 8p |
| مصطلحات موضوعية: |
PROGRAMMED death-ligand 1, NON-small-cell lung carcinoma, THERAPEUTICS, MULTIPLE tumors, ESOPHAGEAL cancer, PEMBROLIZUMAB, CANCER chemotherapy |
| مستخلص: |
Treatment of synchronous multiple primary cancers is clinically difficult. We report four cases of synchronous primary cancers, including advanced and metastatic non-small cell lung cancer (NSCLCs) highly positive for programmed death ligand-1 (PD-L1) expression and initially treated with pembrolizumab. Pembrolizumab was efficacious in 2 patients with NSCLC lesions, followed by chemoradiotherapy for esophageal cancer (case 1) and chemotherapy for gastric cancer (case 2). Both cancers in case 1 showed a complete response for 3 years, while progression of the accompanying gastric cancer resulted in mortality at 20 months in case 2. Both NSCLC and gastric cancer in case 3 failed to respond to pembrolizumab, but the accompanying laryngeal cancer in case 4 showed a complete response, and cytotoxic chemotherapy for NSCLC was continued for 18.0 months. Our clinical experience suggests that pembrolizumab is a useful therapeutic approach for patients with synchronous cancers, including NSCLC that highly expresses PD-L1. [ABSTRACT FROM AUTHOR] |
|
Copyright of Chemotherapy (0009-3157) is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder